Managing patients taking tumour necrosis factor inhibitors

Australian Prescriber

Volumn 29, Issue 3, 2006, Pages 67-70

  Lu, Tim Y T ^a   Hill, Catherine ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Adalimumab; Etanercept; Infliximab; Rheumatology

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; HERPES ZOSTER IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PARACETAMOL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; BLOOD DYSCRASIA; CLINICAL TRIAL; CONFUSION; CRYOTHERAPY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; EMBRYOTOXICITY; GENITAL HERPES; HEADACHE; HEART FAILURE; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JUVENILE RHEUMATOID ARTHRITIS; LACTATION; LEUKOPENIA; LISTERIOSIS; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PANCYTOPENIA; PARESTHESIA; PNEUMONIA; PREGNANCY; PRURITUS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; URTICARIA; VISUAL DISORDER;

EID: 33744723463     PISSN: 03128008     EISSN: 03128008     Source Type: Journal    
DOI: 10.18773/austprescr.2006.042     Document Type: Review

References (11)

1. Lee ATY, Pile K. Disease modifying drugs in adult rheumatoid arthritis. Aust Prescr 2003;26:36-40.
2. McColl G. Tumour necrosis factor alpha inhibitors for the treatment of adult rheumatoid arthritis. Aust Prescr 2004;27:43-6.
3. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
4. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
5. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
6. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
7. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
8. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
9. Roberts L, McColl GJ. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Int Med J 2004;34:687-93.
10. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
11. Nash P, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005;183:205-8.